Catalyst Pharma Partners Licenses GABA Aminotransferase Inhibitors from Northwestern U

Catalyst hopes to develop treatments for addiction and epilepsy based on the compounds, which may be more potent and induce fewer side effects than a related compound that Catalyst previously licensed from Brookhaven National Laboratory and is currently shepherding through clinical trials.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.